Download PDF
Synfacts 2010(7): 0742-0742  
DOI: 10.1055/s-0029-1220018
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of Vaniprevir (MK-7009)

Contributor(s): Philip Kocienski
et al. J. A. McCauley*
Merck Research Laboratories, West Point, USA
Further Information

Publication History

Publication Date:
22 June 2010 (online)

    Permissions and Reprints

Significance

Vaniprevir (MK-7009) is a clinical candidate for the treatment of hepatitis C. It is an HCV NS3/4a protease inhibitor with good plasma and liver exposure in multiple species. The key step in the synthesis is a stereoselective ring-­closing metathesis of dilute solutions (3 mM) of the diene G using the Zhan catalyst H.